儿童Ph染色体阳性急性淋巴细胞白血病治疗争议和思考  

Controversy and consideration on the treatment of acute lymphoblastic leukemia with Philadelphia chromosome-positive in children

作　　者：郭晔 竺晓凡 

机构地区：[1]中国医学科学院血液病医院(血液学研究所)儿童血液病诊疗中心,天津300020

出　　处：《中国实用儿科杂志》2016年第4期260-264,共5页Chinese Journal of Practical Pediatrics

摘　　要：靶向药物酪氨酸激酶抑制剂(TKIs)的发展,极大地改变了人们对儿童Ph染色体阳性急性淋巴细胞白血病(Ph+ALL)的认识。在强化疗联合TKIs治疗取得优越疗效的基础上,造血干细胞移植(HSCT)的地位也出现了争议,进而引发了对HSCT治疗方案的思考。The development of tyrosine kinase inhibitors（TKIs）has revolutionized the therapy of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia（Ph＋ALL）. The prospects for a favorable therapeutic outcome in patients with Ph＋ALL have improved markedly,as demonstrated in a recent study that has combined intensive chemotherapy with TKIs. HSCT is no longer universally recommended for Ph＋ALL. These would give rise to our thinking of the therapy.

关 键 词：酪氨酸激酶抑制剂 PH染色体阳性 急性淋巴细胞白血病 

分 类 号：R72[医药卫生—儿科]